TP53 and leukemia: An extensive Sanger resequencing of 120 candidate cancer genes in diagnostic leukemia samples from 187 children and adolescents with high-risk B-ALL treated with augmented post-induction chemotherapy on the Children’s Oncology Group P9906 protocol and integrated analysis with genome-wide CNAs and gene expression profiles revealed recurrent somatic alterations in key signaling pathways, including B-cell development/differentiation (68 %), TP53/RB tumor suppressor pathway (54 %), Ras signaling (50 %), and Janus kinases (11 %).